Thirty-five years on from the FDA's approval of a first monoclonal antibody, these biologics account for nearly a fifth of the agency's new drug approvals each year. Thirty-five years on from the FDA's approval of a first monoclonal antibody, these biologics account for nearly a fifth of the agency's new drug approvals each year.